Plant Name: Achyranthes bidentata
Collective Molecular Activities at 10μM Activity Cutoff
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GRM5; GRM1; GRM3; GRM2; GRM8; GRM4; | |
| GPBAR1; ADORA3; | |
| TSHR; | |
| PTPN1; PTPN2; CDC25B; | |
| PLA2G1B; RECQL; PKM; AKR1B10; POLB; | |
| GRIA2; GRIK3; GRIK1; GRIA4; GRIK2; GRIK5; | |
| MAPK1; | |
| PPARA; PPARD; | |
| NR1H4; | |
| TLR2; | |
| SLC1A1; | |
| LMNA; FABP3; FABP5; FABP2; FABP4; MAPT; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
| Cytochrome P450 Enzymes: | CYP2D6; |
|---|
Detailed Information of Human Protein Targets
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Enzyme_unclassified | PLA2G1B | Phospholipase A2 group 1B | P04054 | CHEMBL4426 |
| Enzyme_unclassified | RECQL | ATP-dependent DNA helicase Q1 | P46063 | CHEMBL1293236 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Enzyme_unclassified | POLB | DNA polymerase beta | P06746 | CHEMBL2392 |
| Ionotropic glutamate receptor | GRIA2 | Glutamate receptor ionotropic, AMPA 2 | P42262 | CHEMBL4016 |
| Ionotropic glutamate receptor | GRIK3 | Glutamate receptor ionotropic kainate 3 | Q13003 | CHEMBL3684 |
| Ionotropic glutamate receptor | GRIK1 | Glutamate receptor ionotropic kainate 1 | P39086 | CHEMBL1918 |
| Ionotropic glutamate receptor | GRIA4 | Glutamate receptor ionotropic, AMPA 4 | P48058 | CHEMBL3190 |
| Ionotropic glutamate receptor | GRIK2 | Glutamate receptor ionotropic kainate 2 | Q13002 | CHEMBL3683 |
| Ionotropic glutamate receptor | GRIK5 | Glutamate receptor ionotropic kainate 5 | Q16478 | CHEMBL2675 |
| Nuclear hormone receptor subfamily 1 group C | PPARA | Peroxisome proliferator-activated receptor alpha | Q07869 | CHEMBL239 |
| Nuclear hormone receptor subfamily 1 group C | PPARD | Peroxisome proliferator-activated receptor delta | Q03181 | CHEMBL3979 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Protein Kinase | MAPK1 | MAP kinase ERK2 | P28482 | CHEMBL4040 |
| Protein Phosphatase | PTPN1 | Protein-tyrosine phosphatase 1B | P18031 | CHEMBL335 |
| Protein Phosphatase | PTPN2 | T-cell protein-tyrosine phosphatase | P17706 | CHEMBL3807 |
| Protein Phosphatase | CDC25B | Dual specificity phosphatase Cdc25B | P30305 | CHEMBL4804 |
| SLC superfamily of solute carriers | SLC1A1 | Excitatory amino acid transporter 3 | P43005 | CHEMBL2721 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Small molecule receptor (family A GPCR) | ADORA3 | Adenosine A3 receptor | P0DMS8 | CHEMBL256 |
| Small molecule receptor (family C GPCR) | GRM5 | Metabotropic glutamate receptor 5 | P41594 | CHEMBL3227 |
| Small molecule receptor (family C GPCR) | GRM1 | Metabotropic glutamate receptor 1 | Q13255 | CHEMBL3772 |
| Small molecule receptor (family C GPCR) | GRM3 | Metabotropic glutamate receptor 3 | Q14832 | CHEMBL2888 |
| Small molecule receptor (family C GPCR) | GRM2 | Metabotropic glutamate receptor 2 | Q14416 | CHEMBL5137 |
| Small molecule receptor (family C GPCR) | GRM8 | Metabotropic glutamate receptor 8 | O00222 | CHEMBL3228 |
| Small molecule receptor (family C GPCR) | GRM4 | Metabotropic glutamate receptor 4 | Q14833 | CHEMBL2736 |
| Toll-like and Il-1 receptors | TLR2 | Toll-like receptor 2 | O60603 | CHEMBL4163 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | FABP3 | Fatty acid binding protein muscle | P05413 | CHEMBL3344 |
| Unclassified | FABP5 | Fatty acid binding protein epidermal | Q01469 | CHEMBL3674 |
| Unclassified | FABP2 | Fatty acid binding protein intestinal | P12104 | CHEMBL4879 |
| Unclassified | FABP4 | Fatty acid binding protein adipocyte | P15090 | CHEMBL2083 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| CC | GO:0044456; synapse part | GO:0042734; presynaptic membrane | 1.988E-13 | 6.185E-10 | GRIK2, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8 |
| MF | GO:0005215; transporter activity | GO:0005234; extracellularly glutamate-gated ion channel activity | 7.206E-13 | 1.569E-09 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
| MF | Unclassified; | GO:0004872; receptor activity | 3.319E-12 | 5.216E-09 | ADORA3, GPBAR1, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, NR1H4, PPARA, PPARD, TLR2, TSHR |
| BP | GO:0009987; cellular process | GO:0035235; ionotropic glutamate receptor signaling pathway | 6.058E-12 | 6.281E-09 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
| MF | GO:0005215; transporter activity | GO:0015277; kainate selective glutamate receptor activity | 5.073E-11 | 4.602E-08 | GRIK1, GRIK2, GRIK3, GRIK5 |
| MF | Unclassified; | GO:0099600; transmembrane receptor activity | 2.174E-09 | 1.183E-06 | ADORA3, GPBAR1, GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, TSHR |
| BP | GO:0023052; signaling | GO:0060079; excitatory postsynaptic potential | 2.978E-09 | 1.474E-06 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
| CC | GO:0044456; synapse part | GO:0045211; postsynaptic membrane | 1.072E-07 | 4.488E-05 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5, GRM3 |
| BP | GO:0008152; metabolic process | GO:0019433; triglyceride catabolic process | 1.250E-07 | 5.135E-05 | FABP2, FABP3, FABP4, FABP5 |
| BP | GO:0009987; cellular process | GO:0010646; regulation of cell communication | 1.613E-06 | 4.811E-04 | GRIK1, GRIK2, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, LMNA, MAPK1, MAPT, NR1H4, PLA2G1B, PPARD, PTPN1, PTPN2, TLR2 |
| BP | GO:0023052; signaling | GO:0023051; regulation of signaling | 1.948E-06 | 5.581E-04 | GRIK1, GRIK2, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8, LMNA, MAPK1, MAPT, NR1H4, PLA2G1B, PPARD, PTPN1, PTPN2, TLR2 |
| MF | GO:0060089; molecular transducer activity | GO:0001641; group II metabotropic glutamate receptor activity | 3.377E-06 | 8.860E-04 | GRM2, GRM3 |
| CC | GO:0044464; cell part | GO:0042995; cell projection | 4.466E-06 | 1.131E-03 | GRIA2, GRIA4, GRIK3, GRIK5, GRM1, GRM2, GRM3, GRM5, MAPK1, MAPT, PKM, TLR2 |
| BP | GO:0050896; response to stimulus | GO:0032868; response to insulin | 5.656E-06 | 1.416E-03 | FABP3, PKM, PLA2G1B, PPARA, TLR2 |
| BP | GO:0065007; biological regulation | GO:0000187; activation of MAPK activity | 6.497E-06 | 1.538E-03 | GRM1, GRM4, MAPK1, PLA2G1B, PTPN1 |
| BP | GO:0051179; localization | GO:0015908; fatty acid transport | 7.162E-06 | 1.625E-03 | FABP3, PLA2G1B, PPARA, PPARD |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 7.162E-06 | 1.625E-03 | GRIK2, GRIK3, MAPK1, MAPT |
| BP | GO:0050896; response to stimulus | GO:1901701; cellular response to oxygen-containing compound | 7.394E-06 | 1.660E-03 | GRIK5, GRM5, MAPK1, NR1H4, PKM, PLA2G1B, PPARD, TLR2, TSHR |
| BP | Unclassified; | GO:0099566; regulation of postsynaptic cytosolic calcium ion concentration | 1.012E-05 | 2.030E-03 | GRM1, GRM5 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 1.012E-05 | 2.030E-03 | GPBAR1, NR1H4 |
| MF | GO:0060089; molecular transducer activity | GO:0099583; neurotransmitter receptor activity involved in regulation of postsynaptic cytosolic calcium ion concentration | 1.012E-05 | 2.030E-03 | GRM1, GRM5 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 1.012E-05 | 2.030E-03 | GPBAR1, NR1H4 |
| CC | GO:0032991; macromolecular complex | GO:0032983; kainate selective glutamate receptor complex | 1.012E-05 | 2.030E-03 | GRIK2, GRIK5 |
| CC | GO:0044464; cell part | GO:0032839; dendrite cytoplasm | 1.329E-05 | 2.474E-03 | GRIK2, GRIK3, MAPK1 |
| BP | GO:0009987; cellular process | GO:1902202; regulation of hepatocyte growth factor receptor signaling pathway | 2.022E-05 | 3.586E-03 | PTPN1, PTPN2 |
| MF | GO:0005215; transporter activity | GO:0004971; AMPA glutamate receptor activity | 2.022E-05 | 3.586E-03 | GRIA2, GRIA4 |
| MF | GO:0005215; transporter activity | GO:0008381; mechanosensitive ion channel activity | 3.160E-05 | 5.134E-03 | GRIA2, GRIA4, GRIK1, GRIK2, GRIK3, GRIK5 |
| CC | GO:0043226; organelle | GO:0014069; postsynaptic density | 3.133E-05 | 5.134E-03 | GRIK2, GRIK5, GRM1, GRM3, GRM5 |
| BP | GO:0065007; biological regulation | GO:0044092; negative regulation of molecular function | 3.816E-05 | 5.979E-03 | ADORA3, CYP2D6, FABP4, GRM2, GRM3, MAPT, NR1H4, PPARA, PTPN1, PTPN2 |
| BP | GO:0007610; behavior | GO:0007610; behavior | 5.297E-05 | 7.955E-03 | GRIK2, GRM1, GRM5, MAPK1, MAPT, PPARA, TLR2 |
| MF | GO:0005215; transporter activity | GO:0098782; mechanosensitived potassium channel activity | 5.859E-05 | 8.620E-03 | GRIK1, GRIK2, GRIK3, GRIK5 |
| BP | GO:0050896; response to stimulus | GO:0050728; negative regulation of inflammatory response | 6.062E-05 | 8.800E-03 | NR1H4, PPARA, PPARD, PTPN2 |
| CC | GO:0044464; cell part | GO:0043204; perikaryon | 6.062E-05 | 8.800E-03 | GRIK2, GRIK3, GRIK5, MAPK1 |
| BP | GO:0050896; response to stimulus | GO:0009719; response to endogenous stimulus | 6.126E-05 | 8.833E-03 | FABP3, GRM5, MAPK1, NR1H4, PKM, PLA2G1B, PPARA, TLR2, TSHR |
| BP | GO:0009987; cellular process | GO:0007196; adenylate cyclase-inhibiting G-protein coupled glutamate receptor signaling pathway | 1.507E-18 | 1.094E-14 | GRIK3, GRM1, GRM2, GRM3, GRM4, GRM5, GRM8 |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10, ordered by adjusted p-value
Detailed Information of Enriched KEGG Pathways
| Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|
| hsa04724 | Glutamatergic synapse_Homo sapiens_hsa04724 | 5.723E-23 | 8.012E-21 | GRIA2; GRIK5; SLC1A1; GRIK3; GRIK1; GRIK2; GRM1; GRM3; GRM2; GRM5; GRM4; GRM8; MAPK1; GRIA4 |
| hsa04080 | Neuroactive ligand-receptor interaction_Homo sapiens_hsa04080 | 1.988E-17 | 1.392E-15 | GRIA2; GRIK5; GRIK3; GRIK1; GRIK2; TSHR; GRM1; GRM3; GRM2; GRM5; GRM4; ADORA3; GRM8; GRIA4 |
| hsa04072 | Phospholipase D signaling pathway_Homo sapiens_hsa04072 | 6.072E-09 | 2.125E-07 | GRM3; GRM2; GRM5; GRM4; GRM8; MAPK1; GRM1 |
| hsa03320 | PPAR signaling pathway_Homo sapiens_hsa03320 | 2.424E-09 | 1.131E-07 | FABP2; FABP3; FABP4; FABP5; PPARA; PPARD |
| hsa04723 | Retrograde endocannabinoid signaling_Homo sapiens_hsa04723 | 9.896E-07 | 2.771E-05 | GRIA2; GRM5; MAPK1; GRM1; GRIA4 |
| hsa04720 | Long-term potentiation_Homo sapiens_hsa04720 | 5.884E-06 | 1.373E-04 | GRIA2; GRM5; MAPK1; GRM1 |
| hsa04024 | cAMP signaling pathway_Homo sapiens_hsa04024 | 2.721E-05 | 5.442E-04 | GRIA2; MAPK1; PPARA; TSHR; GRIA4 |
| hsa05030 | Cocaine addiction_Homo sapiens_hsa05030 | 9.322E-05 | 1.631E-03 | GRM3; GRIA2; GRM2 |
| hsa04730 | Long-term depression_Homo sapiens_hsa04730 | 1.708E-04 | 2.657E-03 | GRIA2; MAPK1; GRM1 |
| hsa04713 | Circadian entrainment_Homo sapiens_hsa04713 | 6.616E-04 | 8.421E-03 | GRIA2; MAPK1; GRIA4 |
| hsa04540 | Gap junction_Homo sapiens_hsa04540 | 5.291E-04 | 7.407E-03 | GRM5; MAPK1; GRM1 |
| hsa05203 | Viral carcinogenesis_Homo sapiens_hsa05203 | 5.907E-03 | 4.769E-02 | POLB; PKM; MAPK1 |
| hsa05033 | Nicotine addiction_Homo sapiens_hsa05033 | 2.354E-03 | 2.662E-02 | GRIA2; GRIA4 |
| hsa04930 | Type II diabetes mellitus_Homo sapiens_hsa04930 | 3.373E-03 | 3.373E-02 | PKM; MAPK1 |
| hsa05221 | Acute myeloid leukemia_Homo sapiens_hsa05221 | 4.724E-03 | 4.134E-02 | MAPK1; PPARD |
| hsa04923 | Regulation of lipolysis in adipocytes_Homo sapiens_hsa04923 | 4.564E-03 | 4.134E-02 | FABP4; TSHR |
| hsa04975 | Fat digestion and absorption_Homo sapiens_hsa04975 | 2.472E-03 | 2.662E-02 | FABP2; PLA2G1B |
| hsa05031 | Amphetamine addiction_Homo sapiens_hsa05031 | 6.472E-03 | 4.769E-02 | GRIA2; GRIA4 |
| hsa05230 | Central carbon metabolism in cancer_Homo sapiens_hsa05230 | 6.472E-03 | 4.769E-02 | PKM; MAPK1 |
Human Diseases Associated with the Target Proteins of the Plant (Activity≤10μM)
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Linked Targets |
|---|---|---|---|
| A00-B99: Certain infectious and parasitic diseases | Leishmaniasis | B55.0 | PLA2G1B |
| C00-D49: Neoplasms | Melanoma | C43 | TLR2 |
| C00-D49: Neoplasms | Prostate cancer | C61 | TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Major depressive disorder | F32, F33, M32 | GRM3; GRM2; GRM2; GRM5; GRM5 |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Nerve injury | T14.4 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | ADORA3 |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | GRM2; GRM5; PPARD; MAPT |
| W85-W99: Exposure to electric current, radiation and extreme ambient air temperature and pressure | Diagnostic test to differentiate primary and secondary hypothyroidism | W88 | TSHR |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 1 diabetes | E10 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Type 2 diabetes | E11 | PTPN1; PTPN1; GPBAR1; PPARD |
| C00-D49: Neoplasms | Cancer | C00-C96 | ADORA3; MAPK1; TLR2; CDC25B |
| G00-G99: Diseases of the nervous system G00-G99 | Chronic neuropathic pain | G64, G90.0, K21, R52, G89 | GRM5; GRM5 |
| I00-I99: Diseases of the circulatory system | Ischemia | I99.8 | ADORA3 |
| G00-G99: Diseases of the nervous system G00-G99 | Parkinson's disease | G20 | GRIA4; GRIA2 |
| G00-G99: Diseases of the nervous system G00-G99 | Pain | G64, G90.0, R52, G89 | GRIK1; GRM1; PKM |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of moderate to severe corticosteroid-responsive dermatoses of the scalp | L20-L30 | PLA2G1B |
| L00-L99: Diseases of the skin and subcutaneous tissue | Inflammatory and pruritic manifestations of corticosteroid responsive dermatoses | L20-L30 | PLA2G1B |
| E00-E89: Endocrine, nutritional and metabolic diseases | Inflammation | E08-E13, E10.2, E11, E11.2, E13.2, I73.9, I80-I82, N00-N29, G89 | ADORA3 |
| C00-D49: Neoplasms | Inflammatory disease | C11, C44, K75.9, M00-M25 | PLA2G1B |
| NA: NA | Hepatitis C virus infection | NA | ADORA3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Fragile X syndrome | F02.3, G20, Q99.2 | GRM5 |
| C00-D49: Neoplasms | Myelodysplastic syndrome | D46 | TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Anxiety disorder | F32, F40-F42 | GRM3; GRM2; GRM4; GRM5 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Pruritus | L29 | PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Neuropathic pain | G64, G90.0 | GRIK1; GRM1; GRM5 |
| H00-H59: Diseases of the eye and adnexa | Glaucoma | H40-H42 | ADORA3 |
| NA: NA | GERD | NA | GRM5 |
| I00-I99: Diseases of the circulatory system | Restenosis | I51.89 | MAPK1 |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT |
| I00-I99: Diseases of the circulatory system | Neurological disease | I21, I22, R52, R52.1-R52.2, R60.9, G89 | GRIK1; GRM1; GRM4; GRM5 |
| J00-J99: Diseases of the respiratory system | Allergic rhinitis | J00, J30, J31.0, T78.4 | PLA2G1B |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Allergy | T78.4 | PLA2G1B |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | GRM1; GRM3; GRM2; GRM5; MAPT |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Radiation sickness | T66 | TLR2 |
| C00-D49: Neoplasms | Refractory renal cell carcinoma | C64 | PKM |
| E00-E89: Endocrine, nutritional and metabolic diseases | Obesity | E66 | PTPN1; PPARD; PPARD |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Alcohol use disorders | F10.2 | GRIK1 |
| A00-B99: Certain infectious and parasitic diseases | Malaria | B54 | ADORA3; CYP2D6 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Rheumatoid arthritis | M05-M06 | PLA2G1B |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TLR2 |
| L00-L99: Diseases of the skin and subcutaneous tissue | Contact dermatitis | L23, L24, L25 | PLA2G1B |
| NA: NA | Colour dead tissues | NA | PTPN1 |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | MAPK1; TLR2; PKM |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Insomnia | F51.0, G47.0 | CYP2D6 |
| A00-B99: Certain infectious and parasitic diseases | Infections | A00-B99 | PTPN1 |
| C00-D49: Neoplasms | Hepatocellular carcinoma | C22.0 | ADORA3 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Autism | F84.0 | GRM5 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Autoimmune diabetes | E08-E13 | TLR2 |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Bipolar disorder | F31, F40-F42 | GRM2 |
| G00-G99: Diseases of the nervous system G00-G99 | Migraine | G43 | GRM5; CYP2D6 |
| I00-I99: Diseases of the circulatory system | Atherosclerosis | I70 | PPARD |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Mood disorder | F30-F39 | GRM2; GRM5 |
| K00-K95: Diseases of the digestive system | Non-alcoholic fatty liver disease | K76.0 | PPARD |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Huntington's disease | F02.2, G10 | GRM1 |
| M00-M99: Diseases of the musculoskeletal system and connective tissue | Arthritis | M00-M25 | PLA2G1B |
| J00-J99: Diseases of the respiratory system | Asthma | J45 | PLA2G1B |
| C00-D49: Neoplasms | Thyroid cancer | C73 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Psychiatric disorder | F01-F99 | GRM2 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Metabolic disorders | E70-E89 | GPBAR1 |
| NA: NA | Dyslipidemia | NA | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Dyslipidaemias | E78 | PPARD; PPARD |
| A00-B99: Certain infectious and parasitic diseases | Visceral leishmaniasis | B55.0 | PLA2G1B |
| I00-I99: Diseases of the circulatory system | Arteriosclerosis | I70 | PLA2G1B |
| C00-D49: Neoplasms | Thyroid cancer diagnosis | C73 | TSHR |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Schizophrenia | F20 | GRM1; GRM3; GRM2 |
| G00-G99: Diseases of the nervous system G00-G99 | Epilepsy | G40 | GRIK1; GRIK1 |
| E00-E89: Endocrine, nutritional and metabolic diseases | Hyperlipidaemia | E78 | PPARD |
| E00-E89: Endocrine, nutritional and metabolic diseases | Diabetes | E23.2, N25.1 | PTPN1 |